09:39 AM EST, 01/30/2025 (MT Newswires) -- Alterity Therapeutics ( ATHE ) shares were sharply higher Thursday morning after the company said that its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.

The result was achieved at the 50 mg dose at week 52 when compared with placebo, Alterity said.

The company also said that ATH434 was well-tolerated, with no reported serious adverse events.

Price: 5.48, Change: +2.49, Percent Change: +83.28